Clinical Trials Logo

Granuloma Annulare clinical trials

View clinical trials related to Granuloma Annulare.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05650736 Active, not recruiting - Granuloma Annulare Clinical Trials

Janus Kinase Inhibition in Granuloma Annulare

Start date: October 27, 2023
Phase: Phase 2
Study type: Interventional

The primary objective is to determine if JAK1 specific inhibition is effective in treating granuloma annulare (GA), a problematic inflammatory skin disease without an FDA approved treatment. The primary outcome will be the percentage change in the body surface area (BSA) involvement by GA after 6 months of treatment with abrocitinib 200 mg daily in 10 patients with moderate to severe GA affecting at least 5% body surface area (BSA).